Atjaunināt sīkdatņu piekrišanu

Paclitaxel: Sources, Chemistry, Anticancer Actions, and Current Biotechnology [Mīkstie vāki]

Edited by (Department of Botany, Sri Krishnadevaraya University, Anantapur, India), Edited by (Editor of African Journal of Pharmacy and), Edited by (Professor, Department of Biotechnology at East West First Grade College (Affiliated to Bangalore University), India)
  • Formāts: Paperback / softback, 354 pages, height x width: 235x191 mm, weight: 450 g, 100 illustrations (50 in full color); Illustrations
  • Izdošanas datums: 11-Oct-2021
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0323909515
  • ISBN-13: 9780323909518
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 167,86 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
Paclitaxel: Sources, Chemistry, Anticancer Actions, and Current BiotechnologyPalielināt
  • Formāts: Paperback / softback, 354 pages, height x width: 235x191 mm, weight: 450 g, 100 illustrations (50 in full color); Illustrations
  • Izdošanas datums: 11-Oct-2021
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0323909515
  • ISBN-13: 9780323909518
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9780323909518.html
Keywords:

Paclitaxel: Sources, Chemistry, Anticancer Actions, and Current Biotechnology provides a comprehensive survey of Paclitaxel and its derivatives chemistry, biosynthesis and anticancer activities. In addition, biotechnological methods, including cell cultures, the use of bioreactors and metabolic engineering strategies to improve Paclitaxel production are also discussed. The book discusses topics such as mechanisms of action against cancer, novel forms of Paclitaxel for an effective cancer treatment, strategies for enhancing its bioavailability, and the application of nanocarriers for its delivery and chemotherapy of cancer.

This is a valuable resource for cancer researchers, biotechnologists and members of biomedical field who are interested in the promising anticancer qualities of this antineoplastic drug and how to enhance them for better treatments.

  • Presents detailed information about Paclitaxel research, from its discovery to clinical uses and biotechnological routes of commercial production
  • Focuses on Paclitaxel development as an effective chemotherapeutic drug, along with its application in different types of cancers
  • Encompasses descriptive illustrations and workflows to help the reader fully understand the content and easily apply it to their research
Contributors xi
Preface xv
Chapter 1 Introduction to cancer and treatment approaches
1(28)
Madihalli Somashekharaiah Chandraprasad
Abhijit Dey
Mallappa Kumara Swamy
1.1 Introduction
1(2)
1.2 About cancer biology: Causes and risk factors
3(3)
1.3 Cancer types, classification, and grading
6(1)
1.4 Therapeutic interventions for cancer
7(12)
1.5 Advanced approaches for cancer treatment
19(3)
1.6 Conclusions
22(7)
References
23(6)
Chapter 2 Taxol: Occurrence, chemistry, and understanding its molecular mechanisms
29(18)
Mallappa Kumara Swamy
Bala Murali Krishna Vasamsetti
2.1 Introduction
29(2)
2.2 About taxol and its discovery
31(2)
2.3 Natural resources of taxol
33(1)
2.4 Chemistry of taxol
34(1)
2.5 Mechanisms of action of taxol
35(5)
2.6 Conclusion and future prospects
40(7)
References
41(6)
Chapter 3 Taxol: Mechanisms of actiorr against cancer, an update with current research
47(26)
Pei Tee Lim
Bey Hing Goh
Wai-Leng Lee
3.1 The discovery and evolution of Paclitaxel (Taxol)
47(1)
3.2 Paclitaxel (Taxol) induces mitotic cell cycle arrest
48(2)
3.3 Taxol induces gene-directed apoptosis
50(3)
3.4 Taxol and calcium-dependent apoptosis
53(4)
3.5 Immunomodulation effects by Taxol
57(5)
3.6 Resistance mechanisms ofTaxol
62(1)
3.7 Conclusion
63(10)
Acknowledgment
65(1)
References
66(7)
Chapter 4 Application of nanocarriers for paclitaxel delivery and chemotherapy of cancer
73(56)
Saloni Malla
Rabin Neupane
Sai H.S. Boddu
Mariam Sami Abou-Dahech
Mariah Pasternak
Noor Hussein
Charles R. Ashby Jr.
Yuan Tang
R. Jayachandra Babu
Amit K. Tiwari
4.1 Introduction
73(2)
4.2 Nanoparticles
75(8)
4.3 Liposomes
83(8)
4.4 Dendrimers
91(1)
4.5 Micelles
92(1)
4.6 Nanotubes
93(1)
4.7 Niosomes
94(1)
4.8 Proniosomes
94(1)
4.9 Ethosomes
95(1)
4.10 Microparticles
95(1)
4.11 Carbon dots
96(1)
4.12 Clinical trials
96(9)
4.13 Overcoming paclitaxel resistance by using Nanocarriers
105(5)
4.14 Selected patents for paclitaxel formulations
110(4)
4.15 Conclusion
114(15)
References
114(15)
Chapter 5 Strategies for enhancing paclitaxel bioavailability for cancer treatment
129(26)
Mina Salehi
Siamak Farhadi
5.1 Introduction
129(1)
5.2 Alternative paclitaxel sources
130(4)
5.3 Strategies of paclitaxel biosynthesis improvement in plant cell culture
134(10)
5.4 Mathematical modeling for paclitaxel biosynthesis optimization
144(2)
5.5 Concluding remarks and future perspectives
146(9)
References
147(8)
Chapter 6 Botany of paclitaxel producing plants
155(16)
S. Karuppusamy
T. Pullaiah
6.1 History of taxol
155(1)
6.2 Botany of Taxus
156(4)
6.3 Enumeration of taxol producing plant species
160(7)
6.4 Taxol from angiosperms
167(1)
6.5 Conclusions and future direction
168(3)
References
168(3)
Chapter 7 Propagation of paclitaxel biosynthesizing plants
171(32)
T. Pullaiah
S. Karuppusamy
Mallappa Kumara Swamy
7.1 Introduction
171(1)
7.2 Propagation
172(6)
7.3 Micropropagation
178(19)
7.4 Conclusions
197(6)
References
198(5)
Chapter 8 Endophytes for the production of anticancer drug, paclitaxel
203(26)
Mallappa Kumara Swamy
Tuyelee Das
Samapika Nandy
Anuradha Mukherjee
Devendra Kumar Pandey
Abhijit Dey
8.1 Introduction
203(1)
8.2 Paclitaxel sources in nature
204(1)
8.3 Available approaches for paclitaxel production
205(2)
8.4 Endophytes producing paclitaxel from different host plant species
207(9)
8.5 Anticancer properties of endophytes-derived paclitaxel
216(4)
8.6 Conclusions
220(9)
References
221(8)
Chapter 9 Metabolic engineering strategies to enhance the production of anticancer drug, paclitaxel
229(22)
Lakkakula Satish
Yolcu Seher
Kasinathan Rakkammal
Pandiyan Muthuramalingam
Chavakula Rajya Lakshmi
Alavilli Hemasundar
Kakarla Prasanth
Sasanala Shamili
Mallappa Kumara Swamy
Malli Subramanian Dhanarajan
Manikandan Ramesh
9.1 Introduction
229(2)
9.2 Historical perspective of paclitaxel
231(3)
9.3 Metabolic engineering strategies for paclitaxel production
234(12)
9.4 Conclusions
246(5)
References
246(5)
Chapter 10 Paclitaxel and chemoresistance
251(18)
Zhuo-Xun Wu
Jing-Quan Wang
Qingbin Cui
Xiang-Xi Xu
Zhe-Sheng Chen
10.1 Introduction
251(1)
10.2 Mechanisms of chemoresistance
252(4)
10.3 Clinical markers of paclitaxel resistance
256(2)
10.4 Strategies to overcome paclitaxel resistance
258(2)
10.5 Summary
260(9)
References
260(9)
Chapter 11 Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy
269(18)
Elizabeth R. Smith
Zhe-Sheng Chen
Xiang-Xi Xu
11.1 Introduction
269(1)
11.2 Microtubule stabilization and anti-mitotic mechanisms
270(1)
11.3 Mitotic catastrophe
271(1)
11.4 Non-mitotic mechanisms
272(1)
11.5 Importance of micronucleation
273(1)
11.6 Innate immunity leading to the bystander effect
274(1)
11.7 Cellular retention of paclitaxel
275(2)
11.8 Combination therapy
277(2)
11.9 Prospective: New formulation of paclitaxel and additional microtubule stabilizing drugs
279(1)
11.10 Conclusions
280(7)
References
280(7)
Chapter 12 An update on paclitaxel treatment in breast cancer
287(22)
Tuyelee Das
Samapika Nandy
Devendra Kumar Pandey
Abdel Rahman Al-Tawaha
Mallappa Kumara Swamy
Vinay Kumar
Potshangbam Nongdam
Abhijit Dey
12.1 Introduction
287(1)
12.2 Types of breast cancer
288(5)
12.3 Molecular mechanism of paclitaxel in breast cancer
293(1)
12.4 Paclitaxel treatment in different types of breast cancer
294(4)
12.5 Adverse events and resistance due to paclitaxel treatment
298(2)
12.6 Efficiency of other anti-cancer drugs over paclitaxel
300(1)
12.7 Conclusions
300(9)
Acknowledgment
301(1)
References
301(8)
Chapter 13 Paclitaxel conjugated magnetic carbon nanotubes induce apoptosis in breast cancer cells and breast cancer stem cells in vitro
309(24)
Prachi Ghoderao
Sanjay Sahare
Anjali A. Kulkarni
Tejashree Bhave
13.1 Introduction
309(4)
13.2 Experimental details
313(3)
13.3 Results and discussion
316(11)
13.4 Conclusions
327(6)
Acknowledgments
327(1)
Conflict of interest statement
327(1)
References
328(5)
Index 333
Mallappa Kumara Swamy, PhD, completed his Postdoctoral Research at the Department of Crop Science, Faculty of Agriculture, Universiti Putra Malaysia (UPM), from 2014-2018. He has more than 16 years of teaching and research experience in the fields of plant biotechnology, secondary metabolites production, phytochemistry and bioactive studies. Dr. Swamy has published more than 100 research publications in peer- reviewed journals, 25 book chapters and has edited 10 books with reputed international publishers. His research focuses on the area of natural products, plant cell, tissue culture technology for bioactive compounds production and evaluation of their bioactivities, and nanobiotechnology for medical applications. Professor T. Pullaiah is a former Professor at the Department of Botany at Sri Krishnadevaraya University in Andhra Pradesh, India, where he has taught for more than 35 years. He was President of Indian Botanical Society (2014), President of the Indian Association for Angiosperm Taxonomy (2013). He was awarded the Panchanan Maheshwari Gold Medal, the Prof. P.C.Trivedi Medal, the Dr. G. Panigrahi Memorial Lecture award of the Indian Botanical Society and Prof. Y.D. Tyagi Gold Medal of the Indian Association for Angiosperm Taxonomy. Under his guidance 54 students obtained their doctoral degrees. He has authored 52 books, edited 23 books and published over 330 research papers, including reviews and book chapters. He was also a member of Species Survival Commission of the International Union for Conservation of Nature (IUCN). Professor Pullaiah received his PhD from Andhra University, India, attended Moscow State University, Russia, and worked as Post-Doctoral Fellow Zhe-Sheng Chen, PhD, opened the St. Johns Universitys first cancer pharmacology laboratory. His research interest is multidrug resistance and its reversal, novel anti-cancer drug development. Chen has over 170 papers published, co-edited Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy book (Elsevier), and holds 5 patents.